1. Home
  2. ANNX vs MLKN Comparison

ANNX vs MLKN Comparison

Compare ANNX & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.36

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Logo MillerKnoll Inc.

MLKN

MillerKnoll Inc.

HOLD

Current Price

$16.18

Market Cap

1.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
MLKN
Founded
2011
1905
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Office Equipment/Supplies/Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
812.7M
1.0B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
ANNX
MLKN
Price
$5.36
$16.18
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
2.1M
565.0K
Earning Date
05-11-2026
03-25-2026
Dividend Yield
N/A
4.71%
EPS Growth
N/A
N/A
EPS
N/A
0.98
Revenue
N/A
$3,669,900,000.00
Revenue This Year
N/A
$5.94
Revenue Next Year
$16,320.74
$3.78
P/E Ratio
N/A
$16.82
Revenue Growth
N/A
1.14
52 Week Low
$1.85
$13.77
52 Week High
$7.18
$23.18

Technical Indicators

Market Signals
Indicator
ANNX
MLKN
Relative Strength Index (RSI) 48.41 53.81
Support Level $4.80 $13.87
Resistance Level $5.61 $16.34
Average True Range (ATR) 0.28 0.57
MACD 0.02 0.20
Stochastic Oscillator 55.96 86.96

Price Performance

Historical Comparison
ANNX
MLKN

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

Share on Social Networks: